Drug Trial Radar · NCT04646889
Pharmacokinetic Study of AR882 in Subjects With Various Degrees of Renal Impairment
Last checked: Nov 19, 2026Latest source record: Aug 5, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
46
Actual
Start
Jan 14, 2021
Primary completion
Jun 27, 2022
Study completion Jun 27, 2022
Sponsor
- Lead sponsor
- Arthrosi TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- IQVIA Pty Ltd
- First posted
- Nov 30, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a 2-segment, multi-center, phase 1, open-label, study evaluating the pharmacokinetics and pharmacodynamics of AR882 in subjects with various degrees of renal impairment.
Conditions
- Renal Impairment
Interventions
AR882 Single DoseDrug
A single dose of AR882
AR882 Multiple DoseDrug
AR882 taken once daily for 14 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the curve (AUC) for plasma following a single dose of AR882 in subjects with renal impairment and normal renal functionTime frame: 6 days
- Time to maximum plasma concentration (Tmax) following a single dose of AR882 in subjects with renal impairment and normal renal functionTime frame: 6 days
- Maximum plasma concentration (Cmax) following a single dose of AR882 in subjects with renal impairment and normal renal functionTime frame: 6 days
- Terminal half-life (t 1/2) following a single dose of AR882 in subjects with renal impairment and normal renal functionTime frame: 6 days
- Amount excreted (Ae) into urine following a single dose of AR882 in subjects with renal impairment and normal renal functionTime frame: 6 days
- Renal clearance (CLr) following a single dose of AR882 in subjects with renal impairment and normal renal functionTime frame: 6 days
- AUC for plasma following multiple doses of AR882 in subjects with renal impairment and normal renal functionTime frame: 15 days
- Tmax following multiple doses of AR882 in subjects with renal impairment and normal renal functionTime frame: 15 days
- Cmax following multiple doses of AR882 in subjects with renal impairment and normal renal functionTime frame: 15 days
- t 1/2 following multiple doses of AR882 in subjects with renal impairment and normal renal functionTime frame: 15 days
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
Arthrosi Investigative Site
Orlando, Florida
Arthrosi Investigative Site
Dallas, Texas
Arthrosi Investigative Site
Auckland, New Zealand
Arthrosi Investigative Site
Christchurch, New Zealand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.